doi: 10.1007/s43440-022-00413-9.
- PMID: 36220975
- DOI: 10.1007/s43440-022-00413-9
Abstract
Background: The treatment of epilepsy during early life poses unique challenges-first-line therapies leave many individuals with poorly controlled seizures. In response to the pharmaco-resistance of current first-line anti-seizure drugs (ASDs) during early life, new therapies have emerged. One such therapy is cannabidiol (CBD). While well studied in adult models of epilepsy, it is poorly studied in immature animals. Here we assessed the efficacy of CBD in immature rodent models of the epilepsies.
Methods: Pups were pre-treated with CBD (1, 10, 50, 100, 200 mg/kg) and assessed for anticonvulsant efficacy using two well-established anti-seizure screening models: the pentylenetetrazole (PTZ) and maximal electroshock (MES) models. We assessed drug efficacy in postnatal day (P)7 and P21 rats.
Results: In the PTZ model, CBD delayed seizure onset in adolescent but not neonatal rats. By contrast, higher doses of CBD reduced seizure duration in both neonatal and adolescent rats in the MES model. The effects of CBD in both models were modest but consistent.
Conclusion: Efficacy of CBD increased in older as compared to younger animals, producing an age-, model-, and dose-dependent suppression of seizures. These data suggest neonatal seizures (modeled by P7 treatment) may be less responsive to CBD. They also suggest preferential efficacy against tonic seizures as compared to partial motor seizures.
Keywords: Cannabinoid, Electroshock, Epileptogenesis, Neonatal, Pentylenetetrazole
© 2022. The Author(s) under exclusive licence to Maj Institute of Pharmacology Polish Academy of Sciences.
Similar articles
-
Evaluation of Cannabidiol in Animal Seizure Models by the Epilepsy Therapy Screening Program (ETSP).Neurochem Res. 2017 Jul;42(7):1939-1948. doi: 10.1007/s11064-017-2287-8. Epub 2017 May 6.PMID: 28478594
-
Partial protective effects of cannabidiol against PTZ-induced acute seizures in female rats during the proestrus-estrus transition.Epilepsy Behav. 2022 Apr;129:108615. doi: 10.1016/j.yebeh.2022.108615. Epub 2022 Feb 23.PMID: 35217387
-
Anticonvulsive Effects and Pharmacokinetic Profile of Cannabidiol (CBD) in the Pentylenetetrazol (PTZ) or N-Methyl-D-Aspartate (NMDA) Models of Seizures in Infantile Rats.Int J Mol Sci. 2021 Dec 22;23(1):94. doi: 10.3390/ijms23010094.PMID: 35008517 Free PMC article.
-
The Search for New Screening Models of Pharmacoresistant Epilepsy: Is Induction of Acute Seizures in Epileptic Rodents a Suitable Approach?Neurochem Res. 2017 Jul;42(7):1926-1938. doi: 10.1007/s11064-016-2025-7. Epub 2016 Aug 8.PMID: 27502939 Review.
-
Validated animal models for antiseizure drug (ASD) discovery: Advantages and potential pitfalls in ASD screening.Neuropharmacology. 2020 May 1;167:107750. doi: 10.1016/j.neuropharm.2019.107750. Epub 2019 Aug 27.PMID: 31469995 Free PMC article. Review.
References
-
- Painter MJ, Scher MS, Stein AD, et al. Phenobarbital compared with phenytoin for the treatment of neonatal seizures. N Engl J Med. 1999;341:485–9. – DOI
-
- Glass HC, Soul JS, Chu CJ, et al. Response to antiseizure medications in neonates with acute symptomatic seizures. Epilepsia. 2019;60(3):e20–4. – DOI
-
- Zhou C, Sun H, Klein PM, Jensen FE. Neonatal seizures alter NMDA glutamate receptor GluN2A and 3A subunit expression and function in hippocampal CA1 neurons. Front Cell Neurosci. 2015;9:362. – DOI
-
- Holmes GL. The long-term effects of neonatal seizures. Clin Perinatol. 2009;36(4):901–viii. https://doi.org/10.1016/j.clp.2009.07.012 . – DOI
-
- Jensen FE. Neonatal seizures: an update on mechanisms and management. Clin Perinatol. 2009;36(4):881–vii. https://doi.org/10.1016/j.clp.2009.08.001 . – DOI – PubMed – PMC
Grant support
LinkOut – more resources
-
Miscellaneous
